The envelope glycoprotein of the mouse mammary tumor virus (MMTV gp52), a useful plasma marker for mammary tumors in mice, was measured in extracellular medium by radioimmunoassay to quantitatively compare gp52 levels released by a C3H MMTV producer and its subcloned B9 nonproducer cell line. Experiments analyzed levels of viral gp52 released from nonproducer cells both in the presence and absence of dexamethasone (DXS) to compare levels with those of producer cells and to assess quantitative changes in nonproducer release of both soluble and virion-associated gp52. Basal gp52 levels of producer cells were 2.4- to 7.0-fold higher than nonproducer cells. Very little virion-associated gp52 was detected in nonproducer cultures, whereas soluble gp52 was abundant and easily detectable in both cultures. DXS stimulated virus production in B9 cultures, converting nonproducer cells into producers. However, under identical conditions of DXS stimulation, B9 cells never reached the same elevated levels of gp52 as producer cells (90 ng/l06 cells versus 216 ng/l06 cells). Significant soluble gp52 release by B9 cells in the absence of DXS and enhancement in the presence of DXS argues that nonproducer cells can inñuence extracellular levels of viral antigen. By analogy to in vivo studies, results suggest that nonproducer cells in a tumor might also contribute to the pool of gp52 which serves as a systemic plasma marker for tumor.
Murine mammary tumor cells (C3H Mm5mt/cl and B9) were grown in serum-free culture to examine the effects of different polypeptide growth factors on viral glycoprotein (gp52) release into extracellular culture fluids. Epidermal growth factor (EGF) elevated extracellular virion-associated and soluble gp52 levels of mouse mammary tumor virus producer and nonproducer cells. While EGF effectively and consistently elevated gp52 levels at 20 ng/ml, fibroblast growth factor was less effective, and platelet-derived growth factor failed to elevate gp52 levels. Growth factors, EGF and fibroblast growth factor, stimulated cell growth to a greater degree than platelet-derived growth factor and were also more consistently mitogenic. The EGF-mediated elevation in gp52 was statistically significant as compared to controls; however, increases were smaller in magnitude than those obtained with the classical glucocorticoid stimulator, dexamethasone. The results demonstrate that EGF can quantitatively influence extracellular levels of gp52 detected in viral particle and virus-free soluble antigen fractions. These in vitro findings suggest that growth factors such as EGF may play a role in determining tumor cell levels of mouse mammary tumor virus production and levels of gp52 shed as a soluble marker for tumor.
Murine mammary tumor cells (C3H Mm5mt/cl) were grown in charcoal-stripped serum to examine the effects of hormonal treatments on the expression and release of the mouse mammary tumor virus (MMTV) envelope glycoprotein (gp52). The ability of progesterone to modify extracellular levels of soluble and virion-associated MMTV gp52 was tested singly and as a pretreatment prior to dexamethasone (DXS) stimulation. Single treatments with DXS or progesterone demonstrated that DXS was substantially more effective at elevating gp52 than progesterone; however, a small but significant increase in gp52 levels was noted after 72 h of progesterone treatment. Progesterone pretreatments at 10- to 100-fold excess of DXS altered subsequent DXS-stimulated gp52 levels. Progesterone effectively antagonized DXS and reduced gρ52 levels to those of controls but this reduction was accomplished only at the lowest concentrations of DXS (10–8M) and shortest treatment interval (24 h). While some pretreatment protocols of varied dose slightly reduced gp52 levels at a point in time after treatment, the majority of progesterone pretreatments at 10–7,10–6, and 10–5M resulted in MMTV gp52 levels which were equal to and in many cases significantly greater than those obtained with DXS alone. The ability to augment DXS-stimulated gp52 levels with progesterone pretreatment suggests that, under certain hormonal conditions, gp52 expression and release from mouse cells may be progesterone-dependent as well as glucocor-ticoid-dependent.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.